{"entity":{"id":"mga","kind":"target","name":"MGA","aka":["MAX dimerization protein MGA","MAX gene-associated protein","KIAA0518","MAD5","MXD5","FLJ12634"],"tldr":"MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Prostate cancer, Diffuse large B-cell lymphoma and 3 more.","summary":"Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Lung Adenocarcinoma, Pleural Mesothelioma, Prostate Adenocarcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:14010","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14010"},{"label":"UniProt Q8IWI9","url":"https://www.uniprot.org/uniprotkb/Q8IWI9/entry"},{"label":"NCBI Gene 23269","url":"https://www.ncbi.nlm.nih.gov/gene/23269"},{"label":"Ensembl ENSG00000174197","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174197"}],"tags":["cancer-genes-wave"],"related":["civic","intogen"],"cancers":["mesothelioma","prostate","dlbcl","cll","nsclc","pleural-mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"MGA","role":["tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:14010","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14010","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q8IWI9","url":"https://www.uniprot.org/uniprotkb/Q8IWI9/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene MGA","url":"https://civicdb.org/features/9427","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen MGA","url":"https://www.intogen.org/search?gene=MGA","note":"driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"many-types","specificityNote":"Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA MGA: RNA low tissue specificity; high antibody staining in 2 normal tissues. Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Mesothelioma, Prostate cancer, Lymphoma, Leukaemia, Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q8IWI9","url":"https://www.uniprot.org/uniprotkb/Q8IWI9/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene MGA","url":"https://civicdb.org/features/9427","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen MGA","url":"https://www.intogen.org/search?gene=MGA","note":"driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas MGA tissue","url":"https://www.proteinatlas.org/ENSG00000174197-MGA/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000174197 associations","url":"https://platform.opentargets.org/target/ENSG00000174197/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:14010","ensembl":"ENSG00000174197","uniprot":"Q8IWI9","entrez":"23269","firstDescribed":1998,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 1998, \"Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9628581/","biology":"Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes. Suppresses transcriptional activation by MYC and inhibits MYC-dependent cell transformation. Function activated by heterodimerisation with MAX. This heterodimerisation serves the dual function of both generating an E-box-binding heterodimer and simultaneously blocking interaction of a corepressor. Location: Nucleus (UniProt). Locus 15q15 (HGNC).","whereFound":["Mesothelioma: IntOGen driver in 1 cohort (PLMESO)","Prostate cancer: IntOGen driver in 1 cohort (PRAD)","Diffuse large B-cell lymphoma: CIViC evidence names this disease","Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL)","Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUAD)","Pleural mesothelioma: IntOGen driver in 1 cohort (PLMESO)"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/mga/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"}],"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"paper":[{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/"}]}}